why choose us

300×250 Ad Slot

Drug FDA Status

Showing 70 of 196 result(s) (Page 7 of 20)
Drug Name: Inluriyo

Active Ingredient: imlunestrant

Approval Date: 2025-09-25

Description: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Drug Name: Palsonify

Active Ingredient: paltusotine

Approval Date: 2025-09-25

Description: To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

Drug Name: Keytruda Qlex

Active Ingredient: pembrolizumab and berahyaluronidase alfa-pmph

Approval Date: 2025-09-19

Description: To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab 

Drug Name: Forzinity

Active Ingredient: elamipretide

Approval Date: 2025-09-19

Description: To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

Drug Name: Wayrilz

Active Ingredient: rilzabrutinib

Approval Date: 2025-08-29

Description: To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

Drug Name: Dawnzera

Active Ingredient: donidalorsen

Approval Date: 2025-08-21

Description: To prevent attacks of hereditary angioedema
Drug Trials Snapshot

Drug Name: Brinsupri

Active Ingredient: brensocatib

Approval Date: 2025-08-12

Description: To treat non-cystic fibrosis bronchiectasis
Drug Trials Snapshot

Drug Name: Hernexeos

Active Ingredient: zongertinib

Approval Date: 2025-08-08

Description: To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
Drug Trials Snapshot

Drug Name: Modeyso

Active Ingredient: dordaviprone

Approval Date: 2025-08-06

Description: To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
Drug Trials Snapshot

Drug Name: Vizz

Active Ingredient: aceclidine

Approval Date: 2025-07-31

Description: To treat presbyopia

300×250 Ad Slot